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Researching a
deadly disease
with leading
research firm
JMU and SRI ink
formal partnership

By Alex Sharp (’11)
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ina Safavie (’11) has
been fascinated by
viruses since her sophomore year of high
school. This year, the biology
major got hands-on experience
working with a little-known
tropical virus at one of the premier biotech companies in the
world — SRI International.
JMU helped woo SRI International to the Shenandoah Valley
nearly four years ago, and this
summer the university and SRI
signed an agreement that, among
other things, will provide JMU
faculty and students research
opportunities at SRI while
affording SRI employees access
to JMU labs and other resources.
Safavie’s experience at SRI
included adding dengue virus
to “secret” compounds synthesized by SRI, and then adding
that mixture to African green
monkey kidney cells to check
for inhibition of the infection.
An effective compound exhibits
little to no growth of infection.
The World Health Organization states that about 2.5 billion
people are at risk of contracting
mosquito-borne dengue fever,
and that about 500,000 are hospitalized every year for the more
dangerous dengue hemorrhagic
fever. And that is a big problem
since there is no effective treatment for the illness.
“There are no antivirals and
there are no vaccines,” says Safavie, who worked with a research
team seeking an antidote for
dengue fever at SRI’s Center

for Advanced Drug Research.
Safavie worked closely with SRI
virologists to screen various compounds for their anti-viral effects
on the sometimes-fatal virus.
Symptoms of an initial infection are similar to influenza and
include high fever, headaches,
joint pain and rash. People who
are infected a second time can
contract dengue hemorrhagic
fever, a potentially fatal complication that involves a high
fever that lasts from two to seven
days and may be followed by
circulatory failure, which causes
the body temperature to drop
dramatically and the patient to
suffer shock syndrome.
Most cases of dengue fever and
DHF occur in under-developed

tropical nations, says Krishna
Kodukula, director of SRI’s Center for Advanced Drug Research
and leader of the dengue project.
The disease is rare in the United
States, but as global temperatures
increase and the mosquito breeding range broadens, he thinks
there will be more infections and
a larger risk area. “We feel that
more outbreaks will occur in the
U.S.,” Kodukula says, noting that
this summer about 1,000 people
in Key West, Fla., were diagnosed
with dengue fever.
Safavie first learned of dengue
— and the internship offered
by SRI — in a global infectious
diseases class taught by JMU
biology professors Chris Lantz
and Amanda Biesecker. Lantz

‘I always knew that I was into biology,
because with biology, you can explain
life. And sometimes you can also
save lives.’

Tina Safavie (’11) hopes her
hands-on research will help
find a vaccine that prevents the
transmission of the sometimesfatal dengue virus.
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— Tina Safavie (’11), biology major

Tina Safavie (’11) spent part of
her senior year researching
a tropical virus with premier
researchers at SRI International
in Harrisonburg.

has worked directly with SRI
since 2007. “Students who take
this course are very good candidates to move into internships
at SRI,” Lantz says of the threecredit biology class that explores
six global diseases — malaria,
AIDs, tuberculosis, cholera and
little-known tropical diseases
leishmaniasis and dengue fever.
DHF, which is now endemic
in more than 100 countries,
qualifies as a major disease. The
World Health Organization
reports that “not only is the
number of cases increasing as
the disease is spreading to new
areas, but explosive outbreaks
are occurring.” An outbreak
in Venezuela in 2007 involved
more than 80,000 cases of dengue fever, 6,000 of which were
DHF, the agency reported.
Which gives some urgency to
the project at SRI. The goal is to
create an effective anti-virus, and
ideally, a vaccine that prevents
the transmission of dengue.
“I always knew that I was into
biology, because with biology,
you can explain life,” Safavie
says. “And sometimes you can
also save lives.” M
✱ Read more about Safavie’s

research at www.jmu.edu/
news/madisonscholar/2010_
SRI_Intern.shtml

p h o t o g r a p h s b y d i a n e e l l i o t t ( ’ 0 0)

1

